Profile data is unavailable for this security.
About the company
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
- Revenue in USD (TTM)0.00
- Net income in USD-1.18m
- Incorporated2010
- Employees--
- LocationMerrimack Pharmaceuticals IncOne Broadway, 14Th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 441-1000
- Fax+1 (617) 491-1386
- Websitehttps://www.merrimack.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trevi Therapeutics Inc | 0.00 | -29.07m | 208.26m | 25.00 | -- | 2.50 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Zevra Therapeutics Inc | 27.46m | -46.05m | 208.88m | 65.00 | -- | 3.23 | -- | 7.61 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 209.68m | 51.00 | -- | 0.757 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -66.86m | 210.16m | 58.00 | -- | 0.7565 | -- | -- | -1.19 | -1.19 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -21.20 | -- | -21.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 210.49m | 147.00 | -- | -- | -- | 1.80 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Generation Bio Co | 5.90m | -126.61m | 210.77m | 174.00 | -- | 1.03 | -- | 35.70 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Prelude Therapeutics Inc | 0.00 | -121.83m | 212.03m | 128.00 | -- | 0.894 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Renovaro Inc | 0.00 | -41.23m | 215.50m | 12.00 | -- | 2.33 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Omeros Corp | 0.00 | -174.92m | 216.13m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Adverum Biotechnologies Inc | 3.60m | -117.17m | 216.47m | 121.00 | -- | 1.27 | -- | 60.13 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
Ovid Therapeutics Inc | 391.69k | -52.34m | 216.68m | 40.00 | -- | 2.46 | -- | 553.19 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 217.98m | -- | -- | 11.48 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 221.49m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
AVITA Medical Inc | 50.14m | -35.38m | 225.75m | 207.00 | -- | 4.58 | -- | 4.50 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.33 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Western Standard LLCas of 31 Dec 2023 | 2.17m | 14.95% |
Newtyn Management LLCas of 31 Dec 2023 | 1.87m | 12.89% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 692.91k | 4.77% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 587.24k | 4.04% |
Madison Avenue Partners LPas of 31 Dec 2023 | 553.09k | 3.81% |
Adar1 Capital Management LLCas of 31 Dec 2023 | 549.42k | 3.78% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 435.65k | 3.00% |
Sepio Capital LPas of 31 Dec 2023 | 306.68k | 2.11% |
Sio Capital Management LLCas of 31 Dec 2023 | 288.47k | 1.99% |
Geode Capital Management LLCas of 31 Dec 2023 | 259.95k | 1.79% |